96. Med Mal Infect. 2018 Jun;48(4):238-249. doi: 10.1016/j.medmal.2018.01.004. Epub2018 Feb 13.Use of artesunate in non-malarial indications.Raffetin A(1), Bruneel F(2), Roussel C(3), Thellier M(4), Buffet P(5), CaumesE(6), Jauréguiberry S(7).Author information: (1)Service de maladies infectieuses et tropicales et de médecine interne, CHILucie-et-Raymond-Aubrac, 94190 Villeneuve Saint-Georges, France.(2)Service de réanimation médicale, centre hospitalier de Versailles, hôpitalAndré-Mignot, 78150 Le Chesnay, France.(3)Inserm, unité biologie intégrée du globule rouge, laboratoire d'excellenceGR-Ex, Sorbonne universités, université Paris Descartes, INTS, 75015 Paris,France.(4)Centre national de référence pour le paludisme, 75013 Paris, France; Servicede parasitologie-mycologie, groupe hospitalier Pitié-Salpêtrière, AP-HP, 75013Paris, France.(5)Inserm, unité biologie intégrée du globule rouge, laboratoire d'excellenceGR-Ex, Sorbonne universités, université Paris Descartes, INTS, 75015 Paris,France; Centre national de référence pour le paludisme, 75013 Paris, France.(6)Service des maladies infectieuses et tropicales, groupe hospitalierPitié-Salpêtrière, AP-HP, 75013 Paris, France; Inserm, institut Pierre-Louisd'épidémiologie et de santé publique (UMRS 1136), Sorbonne universités, UPMCuniversité Paris 06, 75013 Paris, France.(7)Centre national de référence pour le paludisme, 75013 Paris, France; Servicedes maladies infectieuses et tropicales, groupe hospitalier Pitié-Salpêtrière,AP-HP, 75013 Paris, France; Inserm, institut Pierre-Louis d'épidémiologie et desanté publique (UMRS 1136), Sorbonne universités, UPMC université Paris 06, 75013Paris, France. Electronic address: stephane.jaureguiberry@aphp.fr.INTRODUCTION: Artesunate and other artemisinin derivatives are used in variousinfectious and non-infectious diseases. We aimed to analyze available data onartesunate and artemisinin derivatives activity in humans and their potentialclinical benefits in non-malarial indications.MATERIAL AND METHODS: Literature review performed on PubMed and the CochraneLibrary databases using the PRISMA method. We analyzed studies published inEnglish from January 2008 to August 2017 using the same indicators of drugefficacy.RESULTS: We included 19 studies performed in humans (1 meta-analysis, 1literature review, 4 randomized controlled trials, 3 prospective controlledtrials, 3 prospective uncontrolled trials, 2 exploratory phase 1 or 2 trials, 1case series, and 4 case reports). Artesunate and artemisinin derivativesdemonstrated efficacy in the treatment of schistosomiasis in combination withpraziquantel (P=0.003). Artesunate monotherapy was less effective thanpraziquantel alone (P<0.001) probably because its activity only affects the earlystages of Schistosoma parasites. Artesunate monotherapy could be interesting as achemoprophylactic drug against schistosomiasis (P<0.001). Findings seem promisingbut are still controversial in the treatment of multidrug-resistant CMVinfections. Studies do not conclude on artesunate and artemisinin derivativesefficacy in the treatment of cervix, breast, colorectal, and lung cancers.CONCLUSION: Artesunate and artemisinin derivatives in combination withpraziquantel were effective against schistosomiasis, and could be used as achemoprophylactic drug alone. They could be interesting as anti-CMV andanti-tumor treatment. Additional trials in humans are required to assess theefficacy of artesunate and artemisinin derivatives in diseases other thanmalaria.Copyright © 2018 Elsevier Masson SAS. All rights reserved.DOI: 10.1016/j.medmal.2018.01.004 PMID: 29422423 